Chengdu Olymvax Biopharmaceuticals Balance Sheet Health
Financial Health criteria checks 4/6
Chengdu Olymvax Biopharmaceuticals has a total shareholder equity of CN¥928.4M and total debt of CN¥379.1M, which brings its debt-to-equity ratio to 40.8%. Its total assets and total liabilities are CN¥1.8B and CN¥845.7M respectively. Chengdu Olymvax Biopharmaceuticals's EBIT is CN¥44.8M making its interest coverage ratio 4.4. It has cash and short-term investments of CN¥214.1M.
Key information
40.83%
Debt to equity ratio
CN¥379.05m
Debt
| Interest coverage ratio | 4.4x |
| Cash | CN¥214.08m |
| Equity | CN¥928.37m |
| Total liabilities | CN¥845.66m |
| Total assets | CN¥1.77b |
Recent financial health updates
Is Chengdu Olymvax Biopharmaceuticals (SHSE:688319) Using Too Much Debt?
Feb 12
We Think Chengdu Olymvax Biopharmaceuticals (SHSE:688319) Has A Fair Chunk Of Debt
Sep 30These 4 Measures Indicate That Chengdu Olymvax Biopharmaceuticals (SHSE:688319) Is Using Debt Extensively
Mar 26Recent updates
Subdued Growth No Barrier To Chengdu Olymvax Biopharmaceuticals Inc. (SHSE:688319) With Shares Advancing 35%
Mar 06Is Chengdu Olymvax Biopharmaceuticals (SHSE:688319) Using Too Much Debt?
Feb 12Chengdu Olymvax Biopharmaceuticals Inc. (SHSE:688319) Stock Rockets 40% As Investors Are Less Pessimistic Than Expected
Oct 09We Think Chengdu Olymvax Biopharmaceuticals (SHSE:688319) Has A Fair Chunk Of Debt
Sep 30What Chengdu Olymvax Biopharmaceuticals Inc.'s (SHSE:688319) 26% Share Price Gain Is Not Telling You
Jun 24Is There An Opportunity With Chengdu Olymvax Biopharmaceuticals Inc.'s (SHSE:688319) 27% Undervaluation?
May 28Chengdu Olymvax Biopharmaceuticals Inc. (SHSE:688319) Shares May Have Slumped 25% But Getting In Cheap Is Still Unlikely
Apr 18These 4 Measures Indicate That Chengdu Olymvax Biopharmaceuticals (SHSE:688319) Is Using Debt Extensively
Mar 26Financial Position Analysis
Short Term Liabilities: 688319's short term assets (CN¥864.5M) exceed its short term liabilities (CN¥538.3M).
Long Term Liabilities: 688319's short term assets (CN¥864.5M) exceed its long term liabilities (CN¥307.4M).
Debt to Equity History and Analysis
Debt Level: 688319's net debt to equity ratio (17.8%) is considered satisfactory.
Reducing Debt: 688319's debt to equity ratio has increased from 2.9% to 40.8% over the past 5 years.
Debt Coverage: 688319's debt is not well covered by operating cash flow (8.5%).
Interest Coverage: 688319's interest payments on its debt are well covered by EBIT (4.4x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/30 20:03 |
| End of Day Share Price | 2025/05/30 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Chengdu Olymvax Biopharmaceuticals Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jiabo Zhang | Guosen Securities Co., Ltd. |
| Yinglan Shu | Haitong International Research Limited |
| Jiaxi Xu | Industrial Securities Co. Ltd. |